Published in J Immunol on January 03, 2014
Tryptophan-catabolizing enzymes - party of three. Front Immunol (2014) 0.99
IDO2 in Immunomodulation and Autoimmune Disease. Front Immunol (2014) 0.92
Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol (2015) 0.84
PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res (2015) 0.79
IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. J Immunol (2016) 0.76
Brucella CβG induces a dual pro- and anti-inflammatory response leading to a transient neutrophil recruitment. Virulence (2015) 0.76
Immunomodulatory Factors Galectin-9 and Interferon-Gamma Synergize to Induce Expression of Rate-Limiting Enzymes of the Kynurenine Pathway in the Mouse Hippocampus. Front Immunol (2016) 0.76
IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity. Clin Med Insights Pathol (2016) 0.75
The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System. J Immunol Res (2015) 0.75
Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth. Oncotarget (2016) 0.75
The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs. Sci Rep (2017) 0.75
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Characterization of human blood dendritic cell subsets. Blood (2002) 3.97
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med (2002) 3.97
CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med (1996) 3.82
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today (1999) 3.74
Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 3.18
Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity (2009) 2.86
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol (2006) 2.62
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene (2007) 2.24
Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med (1997) 2.14
Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol (1996) 2.06
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood (2005) 2.01
Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 1.97
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood (2004) 1.83
Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med (2003) 1.78
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol (2008) 1.64
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood (2008) 1.58
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 1.58
Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res (2008) 1.53
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells (2005) 1.47
IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol (2007) 1.46
Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann Rheum Dis (1990) 1.44
To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Med Chem (2009) 1.29
CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest (2007) 1.23
Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem (2011) 1.18
Cell mediated immunity to fungi: a reassessment. Med Mycol (2008) 1.12
Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg (2009) 1.11
Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol (2009) 1.04
Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol (2007) 1.01
Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol (2004) 1.00
Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol (2012) 0.99
Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 0.95
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
Identification of IDO-positive and IDO-negative human dendritic cells after activation by various proinflammatory stimuli. J Immunol (2011) 0.93
1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol (2010) 0.93
Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology (2006) 0.91
The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle. Int J Mol Sci (2013) 0.87
Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol (2003) 0.84
Induction of regulatory T Cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance. Curr Med Chem (2011) 0.82
In vitro HIV infection impairs the capacity of myeloid dendritic cells to induce regulatory T cells. PLoS One (2012) 0.80
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. Ann Hematol (2012) 0.80
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade). Bone Marrow Transplant (2008) 0.77
The Pathway Tools software. Bioinformatics (2002) 14.89
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
The P2X7 receptor: a key player in IL-1 processing and release. J Immunol (2006) 5.35
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med (2005) 4.92
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res (2007) 2.78
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
RhoB and actin polymerization coordinate Src activation with endosome-mediated delivery to the membrane. Dev Cell (2004) 2.13
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood (2007) 2.03
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood (2002) 1.92
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem (2006) 1.81
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity (2005) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood (2011) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood (2006) 1.60
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood (2008) 1.58
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev (2003) 1.48
Nucleofection is an efficient nonviral transfection technique for human bone marrow-derived mesenchymal stem cells. Stem Cells (2005) 1.47
Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther (2003) 1.46
Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica (2005) 1.46
Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med (2003) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
Discovery of a human peptide sequence signaling islet neogenesis. Endocr Pract (2008) 1.38
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol (2002) 1.37
Rotavirus gene silencing by small interfering RNAs. EMBO Rep (2002) 1.36
Cyclin D1 functions in cell migration. Cell Cycle (2006) 1.36
The crystal structure of the BAR domain from human Bin1/amphiphysin II and its implications for molecular recognition. Biochemistry (2006) 1.35
The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol (2009) 1.34
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol (2004) 1.29
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol (2006) 1.28
Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother (2004) 1.27
Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther (2002) 1.27
Conservation of intrinsic disorder in protein domains and families: II. functions of conserved disorder. J Proteome Res (2006) 1.27
Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol (2003) 1.26
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res (2011) 1.25
Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. J Immunol (2009) 1.25
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med (2002) 1.25
Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration. J Biol Chem (2008) 1.25
Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol (2010) 1.24
Exploring the binding diversity of intrinsically disordered proteins involved in one-to-many binding. Protein Sci (2013) 1.23
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22